The pleomorphic pathology of inherited Parkinson's disease: Lessons from LRRK2

Current Neurology and Neuroscience Reports

Volumn 6, Issue 5, 2006, Pages 355-357

  Bonifati, Vincenzo ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ARGININE; CYSTEINE; DOPAMINE; GENE PRODUCT; GLYCINE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; ISOLEUCINE; LEUCINE RICH REPEAT KINASE 2; NEUROFILAMENT PROTEIN; PARKIN; SERINE; TAU PROTEIN; THREONINE; TYROSINE; UBIQUITIN; UNCLASSIFIED DRUG;

AKINESIA; AMINO ACID SUBSTITUTION; AUTOSOMAL DOMINANT INHERITANCE; CELL LOSS; DISEASE DURATION; DISEASE MODEL; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GLIOSIS; HEREDITY; HUMAN; IMMUNOHISTOCHEMISTRY; INHERITANCE; LEWY BODY; MOLECULAR MECHANICS; MUSCLE RIGIDITY; NERVE CELL; NOTE; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN FAMILY; RECESSIVE INHERITANCE; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; TREATMENT OUTCOME; TREMOR;

HUMANS; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 33749011424     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-996-0013-z     Document Type: Note

References (20)

1. Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005, 28:57-87.
2. Zimprich A, Biskup S, Leitner P, et al.: Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
3. Paisan-Ruiz C, Jain S, Evans EW, et al.: Cloning of the gene containing mutations that cause PARKS-linked Parkinson's disease. Neuron 2004, 44:595-600.
4. Bosgraaf L, Van Haastert PJ: Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 2003, 1643:S-10.
5. Mata IF, Kachergus JM, Taylor JP, et al.: Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005, 6:171-177.
6. Berg D, Schweitzer K, Leitner P, et al.: Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 2005, 128:3000-3011.
7. Khan NL, Jain S, Lynch JM, et al.: Mutations in the gene LRRK2 encoding dardarin (PARKS) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005, 128:2786-2796.
8. Di Fonzo A, Tassorelli C, De Mari M, et al.: Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 2006, 14:322-331.
9. Lesage S, Durr A, Tazir M, et al.: LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006, 354:422-423.
10. Ozelius LJ, Senthil G, Saunders-Pullman R, et al.: LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006, 354:424-425.
11. Bras JM, Guerreiro RJ, Ribeiro MH, et al.: G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov Disord 2005, 20:1653-1655.
12. Gaig C, Ezquerra M, Marti MJ, et al.: LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006, 63:377-382.
13. Goldwurm S, Di Fonzo A, Simons EJ, et al.: The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 2005, 42:e65.
14. Funayama M, Hasegawa K, Kowa H, et al.: A new locus for Parkinson's disease (PARKS) maps to chromosome 12p11.2 q13.1. Ann Neurol 2002, 51:296-301.
15. Wszolek ZK, Vieregge P, Uitti RJ, et al.: German-Canadian family (Family A) with parkinsonism, amyotrophy, and dementia - longitudinal observations. Parkinsonism Relat Disord 1997, 3:125-139.
16. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al.: Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004, 62:1619-1622.
17. Gilks WP, Abou-Sleiman PM, Gandhi S, et al.: A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
18. Ross OA, Toft M, Whittle AJ, et al.: Lrrk2 and Lewy body disease. Ann Neurol 2006, 59:388-393.
19. Giasson BI, Covy JP, Bonini NM, et al.: Biochemical and pathological characterization of Lrrk2. Ann Neurol 2006, 59:315-322.
20. Greggio E, Jain S, Kingsbury A, et al.: Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006, In press.